Unlike many cancer therapies, the survival advantage of the amivantamab + lazertinib combination in the MARIPOSA trial isn't static. The benefit progressively increases at 24, 36, and 42 months, suggesting a durable, long-term impact on disease control that grows with extended follow-up.

The control arms (chemotherapy alone) in two major, independent trials, Mariposa 2 and Harmony, both yielded an identical median progression-free survival of 4.4 months. This consistency across studies validates the data and strengthens the conclusion that chemotherapy alone is a poor benchmark post-TKI failure.

Data shows the next-generation KRAS G12C inhibitor deveracib achieves a median progression-free survival (PFS) of 13.8 months as a single agent. This represents a major leap forward, more than doubling the 5-6 month PFS seen with first-generation drugs like sotorasib and adagrasib, signaling a new efficacy benchmark.

Kaplan-Meier curves from the VICTORIA-1 trial show a steep, immediate drop-off for patients on fulvestrant monotherapy, with ~60% progressing quickly. In contrast, the giredestrant combination arms show a much flatter initial curve, visually demonstrating that a primary benefit is protecting the large subset of patients who would otherwise fail therapy very early.

A key emerging characteristic of belzutifan-based therapies is their ability to produce a long-lasting duration of response. This creates a notable "tail of the curve" in survival plots, suggesting belzutifan adds significant durability to combination regimens.

The LITESPARK 011 trial showed the Lenvatinib/Belzutifan combination doubled the duration of response compared to Cabozantinib. This durability, with some patients in remission for over three years, is considered a more significant clinical advance than the modest increase in overall response rate, representing a key differentiator for the regimen.

Despite a more challenging neurocognitive side effect profile, lorlatinib's median progression-free survival (PFS) of over seven years has shifted expert practice. This remarkable efficacy now positions it as the preferred first-line agent over better-tolerated second-generation TKIs for ALK-positive NSCLC.

The progression-free survival (PFS) curves for Belzutifan regimens consistently overlap with controls for 6-8 months before separating. This signature “Belzutifan effect,” seen across multiple trials, suggests the drug provides durable, long-term disease control for a subset of patients rather than immediate, broad efficacy, hinting at a distinct biological mechanism.

The doublet's unique dosing schedule (twice-weekly pills for three weeks, then one week off) is crucial for its long-term success. This "recovery week" per cycle is thought to reduce cumulative toxicity, allowing patients to stay on this highly effective therapy for extended periods.